Rakuten Investment Management Inc. Takes $721,000 Position in Edwards Lifesciences Corporation $EW

Rakuten Investment Management Inc. purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,265 shares of the medical research company’s stock, valued at approximately $721,000.

Several other large investors have also recently modified their holdings of EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth about $266,000. Park Avenue Securities LLC bought a new position in shares of Edwards Lifesciences during the second quarter worth about $315,000. Fifth Third Bancorp lifted its stake in shares of Edwards Lifesciences by 8.5% in the second quarter. Fifth Third Bancorp now owns 23,870 shares of the medical research company’s stock worth $1,867,000 after acquiring an additional 1,865 shares during the period. Ballentine Partners LLC lifted its stake in shares of Edwards Lifesciences by 18.8% in the second quarter. Ballentine Partners LLC now owns 6,072 shares of the medical research company’s stock worth $475,000 after acquiring an additional 963 shares during the period. Finally, Mather Group LLC. boosted its holdings in Edwards Lifesciences by 20.4% in the second quarter. Mather Group LLC. now owns 4,988 shares of the medical research company’s stock valued at $390,000 after acquiring an additional 846 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 57,824 shares of company stock worth $4,863,323 over the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on EW shares. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Royal Bank Of Canada increased their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Piper Sandler restated an “overweight” rating and issued a $98.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a report on Tuesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday. Finally, Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a report on Monday, January 12th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Trading Down 0.9%

NYSE:EW opened at $83.70 on Friday. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.57 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 3.19 and a beta of 0.95. The firm has a fifty day simple moving average of $84.99 and a two-hundred day simple moving average of $80.83.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.